ClinicalTrials.gg
CompletedNCT00486837CF2Updated Aug 21, 2014Results posted

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients

A Phase 2 interventional study of Alpha1-Proteinase Inhibitor (Human) in Cystic Fibrosis, sponsored by Grifols Therapeutics LLC. Completed. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2014-08-21.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
8 Years and older
Sex
All
01

Study summary

The objective of this trial is to determine the optimal region of the lung for depositing Prolastin (alpha-1 antitrypsin; AAT) by inhalation in order to treat cystic fibrosis (CF). The AKITA® nebulizer has settings which can be varied to target the inhaled drug to either the deep lung or to the upper airways in a one to one randomization. The study will measure how much of the activity of the enzyme elastase is inhibited by AAT.

Read the detailed description

The optimum deposition site (bronchial or peripheral) in CF patients for AAT will be investigated by measuring several parameters in induced sputum. The study will start with a 2 week run-in period in which the planned 60 patients inhale isotonic saline once daily. This period is followed by a 4 week treatment period where 30 patients inhale AAT for peripheral deposition and 30 patients inhale AAT for bronchial deposition. Six patients in each group will be asked to collect spontaneous sputum at home.

Twenty-five milligrams of AAT will be deposited at one of the two target sites using the AKITA® device. The inhalation should take place in the evening between 18.00 and 23.00 h.

Patients will inhale saline once daily for 2 weeks (run-in period) followed by 4 weeks of once daily inhalation of AAT. Induced sputum will be collected at visits to the clinic at the start of the run-in, at the start of AAT treatment, and at 2 and 4 weeks after the start of AAT treatment.

02

Conditions studied

  • Cystic Fibrosis

Browse trials for

03

In context

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

This study's enrollment of 72 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

First submitted before Grifols Therapeutics LLC became part of Grifols.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with diagnosis of CF
  • Age >= 8 years
  • Forced expiratory volume at one second () > 25 % of predicted value
  • Free elastase activity checked at visit 1 must be positive (free elastolytic activity in the sample, 2 standard deviations above of the negative blank samples in the assay.) .
  • Patient must be positive at least 3 times for pseudomonas in the last 2 years
  • Patient must be positive for pseudomonas at Visit 1
  • Patient must be able to perform reliable spirometry
  • Patient must be on stable concomitant therapy at least 2 weeks prior to visit 1 and during the study
  • Written of the patient or legal representative(s)

Exclusion criteria

Exclusion Criteria:

  • \< 25% of predicted value post-bronchodilator
  • History of lung transplant
  • Any lung surgery within the past 2 years
  • On any thoracic surgery waiting list
  • Severe concomitant disease (serious malignant disease, congestive heart failure (NYHA) III/IV, cor pulmonale with the need of oxygen therapy)
  • Severe liver cirrhosis with ascites, hypersplenism or grade III/IV esophageal varices.
  • Known selective immunoglobulin A (IgA) deficiency with known antibody against IgA (anti-IgA antibody)
  • Active pulmonary exacerbation within the 4 weeks prior to screening
  • Current Smoking
  • Pregnancy or lactation
  • Women of child-bearing age without adequate
  • Any medical condition which the investigator feels will prohibit the patient from completing the trial
  • Participation in another clinical trial within 30 days prior to inclusion at visit 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Group 1

    Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks

    Drug: Alpha1-Proteinase Inhibitor (Human)

  • Experimental
    Group 2

    Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks

    Drug: Alpha1-Proteinase Inhibitor (Human)

Interventions

  • 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.

    Also known as: Prolastin®, Alpha-1 antitrypsin (AAT), BAY x 5747, BAY 10-5233, TAL-05-00007, A1AT, NDC 13533-601-30, NDC 13533-601-35

06

What researchers measure

Primary outcomes

  1. Change in Free Elastase in Induced Sputum From Baseline to Week 4

    Time frame: Baseline vs Week 4

Secondary outcomes

  1. Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4

    Time frame: Baseline vs Week 4

  2. Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4

    Time frame: Baseline vs Week 4

  3. Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4

    Time frame: Week 4

  4. Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4

    Time frame: Baseline vs Week 4

  5. Change in Neutrophil Number in Induced Sputum From Baseline at Week 4

    Time frame: Baseline vs Week 4

07

Results

Posted Aug 21, 2014

Participant flow

This study was performed in 8 study centers in Germany.

Participant flow — Overall Study
MilestonePeripheral DepositionBronchial Deposition
Started3735
Completed2828
Not completed97
Withdrew: Withdrawal by subject10
Withdrew: Adverse event11
Withdrew: Protocol violation42
Withdrew: No sputum, devise issues, exacerbation34

Outcome measures

PrimaryChange in Free Elastase in Induced Sputum From Baseline to Week 4
Time frame:
Baseline vs Week 4
Reported as:
Mean · ug/mL
Change in Free Elastase in Induced Sputum From Baseline to Week 4
ug/mLPeripheral DepositionBronchial Deposition
Change in Free Elastase in Induced Sputum From Baseline to Week 4-7.42 ± 29.966.11 ± 31.30
Statistical analysis
  • Peripheral Deposition vs Bronchial Deposition · ANCOVA · p = 0.197
SecondaryChange in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4
Time frame:
Baseline vs Week 4
Reported as:
Mean · ug/mL
Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4
ug/mLGroup 1Group 2
Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 416741 ± 335836469 ± 18999
SecondaryChange in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4
Time frame:
Baseline vs Week 4
Reported as:
Mean · ug/mL
Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4
ug/mLGroup 1Group 2
Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 40.005 ± 1.10-0.48 ± 1.53
SecondaryChange in Total Bacterial Load in Induced Sputum From Baseline to Week 4
Time frame:
Week 4
Reported as:
Mean · CFU/g
Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4
CFU/gGroup 1Group 2
Change in Total Bacterial Load in Induced Sputum From Baseline to Week 422673275.8 ± 253455845.235021353.2 ± 130686274.77
SecondaryChange in Pseudomonas Load in Induced Sputum From Baseline at Week 4
Time frame:
Baseline vs Week 4
Reported as:
Mean · CFU/g
Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4
CFU/gGroup 1Group 2
Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4-40.1 ± 808.2-22.3 ± 772.4
SecondaryChange in Neutrophil Number in Induced Sputum From Baseline at Week 4
Time frame:
Baseline vs Week 4
Reported as:
Mean · percentage of change
Change in Neutrophil Number in Induced Sputum From Baseline at Week 4
percentage of changeGroup 1Group 2
Change in Neutrophil Number in Induced Sputum From Baseline at Week 4-20.8 ± 30.3-8.2 ± 20.9

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peripheral Deposition—0/37 (0%)10/37 (27%)
Bronchial Deposition—0/35 (0%)13/35 (37.1%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPeripheral DepositionBronchial Deposition
NasopharyngitisInfections and infestations1/375/35
FatigueGeneral disorders0/372/35
HaemoptysisRespiratory, thoracic and mediastinal disorders1/372/35
Back painMusculoskeletal and connective tissue disorders2/370/35
Conjunctivitis AllergicEye disorders0/371/35
Abdominal PainGastrointestinal disorders0/371/35
DiarrhoeaGastrointestinal disorders0/371/35
GingivitisGastrointestinal disorders0/371/35
SinusitisInfections and infestations0/371/35
CoughRespiratory, thoracic and mediastinal disorders0/371/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Peripheral DepositionBronchial DepositionTotal
<=18 years101020
Between 18 and 65 years272552
>=65 years000
Age, Continuous
Age, Continuous(years)Peripheral DepositionBronchial DepositionTotal
Mean23.78 ± 7.5427.42 ± 9.7825.46 ± 8.84
Sex: Female, Male
Sex: Female, Male(Participants)Peripheral DepositionBronchial DepositionTotal
Female211940
Male161632
Region of Enrollment
Region of Enrollment(participants)Peripheral DepositionBronchial DepositionTotal
Germany373572
Free Elastase during the Run-In Phase
Free Elastase during the Run-In Phase(µg/mL)Peripheral DepositionBronchial DepositionTotal
Week 036.6 ± 35.935.9 ± 38.836.2 ± 36.9
Week 232.7 ± 31.725.0 ± 20.129.1 ± 27.0
Absolute Change-4.0 ± 21.3-10.9 ± 36.9-7.25 ± 29.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007 Feb;29(2):240-50. doi: 10.1183/09031936.00047306. Epub 2006 Oct 18. PubMed 17050563 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Jun 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 10 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2007
First posted
Jun 15, 2007
Start
Dec 2003
Primary completionActual
Jun 2004
CompletionActual
Jun 2004
Results first posted
Aug 21, 2014
Last update
Aug 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00486837
Responsible party
Sponsor
First posted
Jun 15, 2007
Start date
Dec 2003
Primary completion
Jun 2004
Completion
Jun 2004
Results posted
Aug 21, 2014
Last update
Aug 21, 2014

Study contacts

Matthias Griese, MD
principal investigator · Kinderklinik und Kinderpoliklinik im Haunerschen Kinderspital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion